Breaking · World's first CAR-T for gastric/GEJ cancer approved in China.Check if you qualify — free

Back to Resources
Cancer Care

Cancer Care in China

Specialist Oncology Resources for International Patients.

An overview of China's oncology landscape for international patients — covering leading cancer hospitals, specialist departments, MDT review processes, cell therapy infrastructure, and how to plan a cancer care journey to China.

Featured Specialty Areas

Featured Specialty Areas in China

Explore specialized care pathways where China may offer important options for international patients and families facing complex cancer or blood disorder decisions.

Specialty Area

Pediatric Leukemia & Blood Disorders

For families facing pediatric leukemia, donor shortage, relapse, refractory disease, or complex transplant decisions.

Explore Pediatric Hematology
Specialty Area

CAR-T & Cell Therapy

Information on CAR-T therapy, cell therapy access, relapse situations, and how international families may seek expert review in China.

Explore CAR-T in China
Specialty Area

Haploidentical Transplant

Guidance on parent donors, no matched donor situations, donor shortage, and China's experience with haploidentical transplantation.

Explore Haplo Transplant
Specialty Area

Rare Blood Disorders

For rare pediatric and adult blood disorders, inherited marrow failure syndromes, immune disorders, and cases where local options are limited.

Explore Rare Blood Disorders

Articles & Guides

June 10, 2026
Colon Cancer Treatment Guide

Colon Cancer Treatment in China: Targeted Therapy, Surgery, and Access for International Patients

China diagnoses more than 500,000 new colorectal cancer cases annually. A guide to FOLFOX and CAPOX chemotherapy, bevacizumab, anti-EGFR cetuximab, BRAF V600E targeted therapy, MSI-H immunotherapy with pembrolizumab, China-developed fruquintinib (呋喹替尼 — now also FDA-approved globally), liver metastasis surgery, conversion therapy, and HIPEC for peritoneal disease.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • 500,000+ new colorectal cancer cases annually in China — deep caseload experience across all disease stages, molecular subtypes, and treatment lines
  • China-developed fruquintinib (FRESCO trial in China → FRESCO-2 global trial → FDA approval 2023) — available in China before global markets
  • MSI-H/dMMR colorectal cancer: pembrolizumab first-line immunotherapy (KEYNOTE-177) available in China; MSI/MMR testing determines eligibility
  • High-volume liver metastasis surgery and conversion therapy — converting initially unresectable liver metastases to resectable through MDT-driven combination treatment

Important Facts

  • RAS (KRAS/NRAS), BRAF V600E, MSI/MMR, HER2, and tumour sidedness testing are all required before metastatic treatment planning — incomplete profiling leads to suboptimal decisions
  • Fruquintinib (呋喹替尼) is a China-developed VEGFR inhibitor approved for refractory mCRC — available in China before receiving global FDA approval in 2023
  • MSI-H/dMMR patients should receive pembrolizumab first-line rather than standard chemotherapy — a result that changes treatment completely
  • Liver metastasis resectability should be assessed by a hepatobiliary surgeon, not medical oncology alone — conversion therapy is a defined treatment goal at Chinese centres
June 9, 2026
Ovarian Cancer Treatment Guide

Ovarian Cancer Treatment in China: PARP Inhibitors, Surgery, and Access for International Patients

China diagnoses more than 60,000 new ovarian cancer cases annually. A guide to cytoreductive surgery, carboplatin chemotherapy, bevacizumab, and the full PARP inhibitor landscape — including internationally approved olaparib and niraparib, plus China-developed fuzuloparib (氟唑帕利) and senaparib (西那帕利) not widely available elsewhere.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • 60,000+ new ovarian cancer cases annually in China — deep caseload experience across all disease stages and subtypes
  • China-developed fuzuloparib (FZOCUS-2 trial) NMPA-approved for platinum-sensitive recurrent and first-line BRCA-mutated ovarian cancer
  • China-developed senaparib approved for BRCA-mutated or HRD-positive recurrent ovarian cancer — broader eligibility than BRCA-only agents
  • HRD testing widely available at major Chinese centres — determines eligibility for niraparib and senaparib beyond BRCA-mutated disease

Important Facts

  • BRCA1/2 testing and HRD assessment are the foundation of ovarian cancer treatment decisions — and determine PARP inhibitor eligibility
  • Fuzuloparib and senaparib are China-developed PARP inhibitors with NMPA approval not available in most other countries
  • Cytoreductive surgery quality — specifically R0 resection — significantly influences long-term outcomes; surgical volume matters
  • Platinum-sensitive versus platinum-resistant relapse distinction drives all subsequent treatment sequencing decisions
June 2, 2026
Decision Guide

Why Do Some International Families Consider China for Complex Blood Disorders?

A candid decision-support guide covering the five specific situations that lead international families to seek specialist blood disorder care in China: no matched donor, disease relapse, rare conditions requiring high-volume centres, CAR-T access, and structured second opinion. Includes honest assessment of when China is not the right answer.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • Five specific situations: no matched donor, relapse, rare disease, CAR-T access, second opinion
  • Haploidentical transplant solves the donor shortage problem — parents can always donate
  • Thalassaemia, aplastic anaemia, Fanconi anaemia, JMML, CAEBV — China's large cohorts
  • Honest about when seeking care in China is unlikely to help

Important Facts

  • Most families who consider China have reached a specific clinical impasse — not a vague preference
  • Haploidentical (parent donor) transplant: China accounts for the world's largest published experience
  • CAR-T and clinical trial access vary; online MDT consultation is the right first step to assess fit
  • Post-treatment coordination with home-country physicians must be planned before treatment begins
May 31, 2026
Breast Cancer Treatment Guide

Breast Cancer Treatment in China: Targeted Therapy, Innovative Drugs & International Patient Access

China diagnoses more than 400,000 new breast cancer cases annually, giving Chinese oncologists extensive caseload experience across all subtypes. A guide to HER2-targeted therapy (trastuzumab, pertuzumab, DS-8201, plus China-developed pyrotinib and inetetamab), CDK4/6 inhibitors (including China-developed dalpiciclib), PARP inhibitors for BRCA-mutated disease, TNBC immunotherapy, and the expanding ADC landscape.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • 400,000+ new breast cancer cases annually in China — deepest caseload experience globally
  • China-developed pyrotinib (PHOEBE trial) showed superiority over lapatinib in HER2+ disease
  • China-developed dalpiciclib (DAWNA-1 trial) for HR+/HER2- metastatic breast cancer
  • DS-8201 expanded treatment to HER2-low disease — ~50–60% of all breast cancers

Important Facts

  • Biomarker profiling (HER2, ER/PR, Ki-67, BRCA, PD-L1, PIK3CA) is the foundation of treatment decisions
  • Pyrotinib and inetetamab are China-developed HER2-targeted therapies not available in many other countries
  • Dalpiciclib is a China-developed CDK4/6 inhibitor approved for HR+/HER2- metastatic breast cancer
  • HER2-low — IHC 1+ or 2+/FISH-negative — is now a targetable category via DS-8201 ADC
May 30, 2026
Gastric Cancer Treatment Guide

Gastric Cancer Treatment in China: Targeted Therapy, Immunotherapy, and the Coming World-First Solid Tumour CAR-T

China records approximately 40% of global gastric cancer cases — more than 400,000 per year. A guide to HER2-targeted therapy, PD-1 immunotherapy (including China-developed drugs), Claudin18.2 antibody treatment, and CT041: the CAR-T in advanced regulatory review that could become the world's first approved solid tumour CAR-T.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • ~40% of global gastric cancer cases diagnosed in China annually
  • HER2-targeted therapy: trastuzumab, DS-8201, and China-developed RC48 ADC
  • PD-1 immunotherapy including China-developed sintilimab and serplulimab
  • Claudin18.2: from zolbetuximab antibody to CT041 — potential first solid tumour CAR-T

Important Facts

  • China records ~40% of global gastric cancer cases, giving oncologists unmatched caseload experience
  • China-developed RC48 ADC active in HER2 low/intermediate expression — broader eligibility than global approvals
  • CT041 Claudin18.2 CAR-T in advanced NMPA regulatory review — potential world-first solid tumour CAR-T
  • Multiple China-developed PD-1 inhibitors approved and reimbursed at lower cost than originator drugs
May 29, 2026
Lung Cancer Treatment Guide

Lung Cancer Treatment in China: Targeted Therapy, Immunotherapy, and Why Caseload Matters

China treats more than 700,000 new lung cancer cases annually. A guide to EGFR targeted therapy, ALK inhibitors, MET inhibitors, PD-1 immunotherapy, and China-developed innovative drugs — including aumolertinib, furmonertinib, and savolitinib — for international patients seeking treatment or a second opinion.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • Why China's lung cancer caseload (700,000+ cases/year) translates into deep clinical expertise in EGFR, ALK, MET, and immunotherapy
  • China-developed EGFR inhibitors: aumolertinib (艾弗沙) and furmonertinib (伏美替尼) — NMPA approved, not yet available in all other countries
  • China-developed PD-1 inhibitors for NSCLC: sintilimab, camrelizumab, tislelizumab, sugemalimab
  • When a Chinese MDT second opinion is relevant — rare mutations, drug access, resistance sequencing

Important Facts

  • EGFR mutations are found in ~50% of NSCLC in East Asian patients — Chinese oncologists have exceptional experience managing EGFR-targeted therapy and resistance
  • China-developed 3rd-gen EGFR inhibitors (aumolertinib, furmonertinib) and MET inhibitor savolitinib are available in China but not widely accessible elsewhere
  • Multiple China-developed PD-1 inhibitors with NMPA approval for lung cancer indications offer cost advantages with published clinical data
  • A remote structured case review is the appropriate first step for international patients before any travel decision
May 27, 2026
International Care Guide

When Should Families Consider Treatment Abroad for Pediatric Leukemia?

A structured guide for families evaluating whether international treatment may be relevant — what situations typically trigger the consideration, how to evaluate it, and what the process involves in practice.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • Six situations where international treatment may be worth evaluating: donor shortage, relapse, refractory disease, CAR-T access, differing opinions, rare diagnosis
  • Why China may be relevant — haploidentical transplant, CAR-T, and combined pathway experience
  • A five-step practical framework: start with remote second opinion before any travel commitment
  • What physical treatment in China actually involves — timeline, logistics, caregiver planning

Important Facts

  • International treatment is worth evaluating when local options are genuinely limited — not as a first reaction
  • A structured remote second opinion is the appropriate first step, not immediate travel
  • China has substantial documented experience in haploidentical transplant, CAR-T, and post-transplant relapse management
  • International consultation works best as a supplement to, not replacement for, the local treating team
May 27, 2026
Treatment Decision Guide

CAR-T vs Bone Marrow Transplant: How Do Families Decide?

A structured guide on how families decide between CAR-T therapy and bone marrow transplant — covering how they differ, when each is used, sequencing, eligibility factors, and how MDT review helps families navigate this decision.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • How CAR-T and bone marrow transplant differ in mechanism, timing, and role
  • When each is typically used — and why they are often used in sequence, not as alternatives
  • Why CAR-T as a bridge to transplant is the most common combined pathway in pediatric relapsed ALL
  • Five questions families should ask when trying to understand the treatment plan

Important Facts

  • CAR-T and transplant are different treatments serving different roles — often used in sequence, not as alternatives
  • CAR-T is most commonly used to achieve remission before transplant in relapsed pediatric leukemia
  • Whether CAR-T is a bridge to transplant or a standalone treatment depends on disease biology and MDT assessment
  • A structured review is most useful when families are trying to understand sequencing and eligibility
May 27, 2026
Relapse & Refractory Guide

What Are the Options If Leukemia Comes Back After Transplant?

A structured guide for families facing post-transplant relapse — covering what the situation means, what options may be evaluated including DLI, CAR-T, second transplant and clinical trials, and how families can seek expert guidance.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • Types of post-transplant relapse — molecular vs haematological, early vs late — and why timing matters
  • Five main options: DLI, CAR-T, salvage chemotherapy, second transplant, clinical trials
  • A practical five-step framework for families facing post-transplant relapse
  • Why international centres with specific experience may be relevant in this situation

Important Facts

  • Post-transplant relapse does not automatically mean all options are exhausted
  • DLI is most effective for molecular relapse; CAR-T and second transplant require individual eligibility assessment
  • The type and speed of relapse significantly influences which options are available and how urgently decisions must be made
  • Specialist review is strongly recommended in this situation — it is one of the most complex scenarios in haematology
May 27, 2026
Pediatric Transplant Guide

Is Haploidentical Transplant Safe for Children?

A clear guide on haploidentical transplant safety in children — covering what the real risks are, what published evidence from the Beijing Protocol and international studies shows, how modern protocols have improved outcomes, and how families can evaluate whether this approach may be appropriate.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • Four main risks explained: GVHD, infection, graft failure, conditioning toxicity — and how each is managed
  • How modern protocols including PTCy and T-cell management have improved outcomes
  • What the published evidence shows — and what it does not show
  • Six key questions families should ask when evaluating suitability for their child

Important Facts

  • Haploidentical transplantation is not experimental — it is supported by published data in major international journals
  • Risks are real but modern protocols have significantly improved outcomes compared with older transplant eras
  • Published outcomes data exists for both adult and pediatric applications of the Beijing Protocol
  • Whether haplo-HSCT is appropriate for a specific child requires individual clinical assessment
May 27, 2026
Pediatric Transplant Guide

Can Parents Become Bone Marrow Donors for Their Child?

A guide to haploidentical donation from a parent — what it means biologically, how donor evaluation works, which parent is typically chosen, what stem cell collection involves for the parent, and what risks exist for both donor and recipient.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • Why parents are haploidentical donors by definition — what this means biologically
  • How donor evaluation works: HLA subtyping, antibody testing, donor health, infection screening
  • How stem cells are collected from a parent — peripheral blood collection, not usually bone marrow harvest
  • Risks for the child: GVHD, infection, and graft failure — and how modern protocols manage them

Important Facts

  • Parents share approximately 50% of HLA antigens with their children — making them haploidentical donors by definition
  • Both parents are biologically eligible; the choice between them depends on HLA details, antibody status, and health
  • Stem cell collection from the parent is typically via peripheral blood apheresis, not bone marrow harvest
  • Haploidentical transplantation using a parent donor has substantial published evidence from specialist centres
May 27, 2026
Pediatric Transplant Guide

What Happens If My Child Has No Matched Donor?

A guide for families facing donor shortage — what "no matched donor" actually means, what alternative donor options exist, how haploidentical transplantation works, why China has substantial experience in this area, and a practical framework for navigating donor shortage situations.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • What "no matched donor" means — and what alternative donor options may still exist
  • Why parents can become haploidentical donors — and what evaluation involves
  • China's experience with haploidentical transplantation and why donor shortage is a specific area of strength
  • A five-step practical framework for families navigating donor shortage situations

Important Facts

  • No matched sibling donor does not automatically end transplant possibilities
  • Modern pediatric transplant programs use haploidentical, unrelated, and cord blood donors effectively
  • Chinese haematology centres have developed substantial experience in haploidentical transplantation, partly because of historically lower matched donor availability
  • Transplant timing and disease control are evaluated alongside donor matching — not in isolation
May 26, 2026
Treatment Guide

What to Expect When Chemotherapy Continues After Cancer Seems Gone

A clear guide for international patients and caregivers on why chemotherapy may continue after scans show no visible cancer — covering NED, adjuvant therapy, microscopic residual disease, recurrence risk, the emotional confusion that often follows remission, and how supportive care in China including TCM fits alongside ongoing treatment.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • NED explained: what no evidence of disease means and what it does not guarantee about microscopic cancer cells
  • Why cancer treatment happens in phases — and why continued chemotherapy after apparent remission is often planned from the start
  • What post-remission chemotherapy means in solid tumours, blood cancers, and paediatric cancers — each type explained separately
  • Supportive care in China during continued chemotherapy: TCM, acupuncture, and integrative approaches alongside standard treatment

Important Facts

  • Continued chemotherapy after cancer appears gone is not a sign of treatment failure — it is often a planned phase of care
  • For international patients, MDT review can clarify why chemotherapy continues and how treatment sequencing works
  • Supportive care in China may include TCM-based approaches to manage fatigue, sleep, and appetite during prolonged chemotherapy
May 2, 2026
Screening Guide

Why Routine Medical Checks Miss Early Cancer — and How to Catch Them Earlier

A practical guide for international patients and caregivers on why routine health checks miss early cancer, which cancers are hardest to detect without targeted screening, how cancer-specific screening in China differs from general check-ups, and how MDT second opinion can identify gaps in prior evaluation for international patients.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • Why normal check-up results do not exclude early cancer — and the key limitation of routine health monitoring vs targeted screening
  • Cancers most likely to be missed in routine checks: pancreatic, ovarian, non-smoking lung cancer, gastrointestinal
  • How cancer screening in China — including endoscopy, LDCT, and MDT coordination — improves early detection for international patients
  • When to pursue a second opinion or MDT evaluation to identify gaps in prior screening or evaluation

Important Facts

  • "Normal check-up" does not equal "no cancer" — the right tests must be selected based on individual risk
  • Cancer-specific screening in China offers accessible endoscopy, imaging, and MDT coordination for international patients
  • Risk-based selection is more valuable than comprehensive maximum-testing packages
  • MDT second opinion can review prior results and identify whether targeted screening was missing
May 1, 2026
Practical Guide

Should Lung Cancer Patients Exercise During Treatment?

A practical guide for international lung cancer patients and caregivers on exercise safety during treatment in China — covering appropriate activity types, warning signs, a five-step safe-start framework, and how breathing-focused supportive care including Tai Chi, Qigong, and TCM approaches complement a gentle exercise routine alongside standard oncology treatment.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • Exercise during lung cancer treatment: why it helps and what types are appropriate for international patients in China
  • Warning signs to stop vs signals to modify — and how MDT coordination integrates exercise guidance with treatment planning
  • Supportive care in China: Tai Chi, Qigong, breathing practices, acupuncture for fatigue and breathlessness alongside standard treatment
  • Caregiver guidance for supporting safe, consistent activity without pressure

Important Facts

  • Light consistent exercise is generally safe and beneficial during lung cancer treatment when matched to current condition
  • Breathing exercises are particularly valuable for lung cancer patients and can be practised even when other activity is limited
  • MDT-coordinated care in China aligns activity recommendations with treatment phases, blood counts, and symptom management
  • TCM approaches including Tai Chi and Qigong offer breathing-focused movement well-suited to lung cancer patients
April 30, 2026
Practical Guide

Balancing Cancer Treatment Side Effects with Living Fully During Recovery

A practical guide for international cancer patients and caregivers on managing treatment side effects while maintaining meaningful daily activities in China — covering activity and rest balance, a five-step framework, how treatment plans can be adjusted for quality of life, and how integrated supportive care including TCM supports this balance alongside standard oncology treatment.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • Practical balance between activity and rest during treatment cycles in China
  • Five-step framework: defining living fully, understanding cycle patterns, adjusting expectations, flexible routines, structured coordination
  • TCM and integrative supportive care alongside standard oncology treatment in China
  • Caregiver guidance for supporting balance without creating pressure

Important Facts

  • Balancing treatment and daily life requires adjusting expectations and building a flexible rhythm specific to treatment cycle patterns
  • Early communication with the oncology team allows treatment dose, schedule, or supportive care to be adjusted for quality of life
  • Structured MDT coordination in China helps align symptom management with overall treatment goals for international patients
  • TCM and integrative supportive care are used alongside — not instead of — standard oncology treatment
April 30, 2026
Treatment Guide

Stage 4 Cancer Remission: How Often It Happens and What Makes It Possible

A calm, honest guide for international patients and caregivers on stage 4 cancer remission — covering what different response types mean, which cancers are more likely to achieve remission, how molecular factors influence outcomes, a five-step evaluation framework, and how MDT review in China supports clear, realistic treatment planning for stage 4 cases.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • Complete remission, partial remission, stable disease, and long-term disease control — what each means for stage 4 patients and caregivers
  • Cancer types with higher remission potential: blood cancers, immunotherapy-responsive melanoma, lung cancer with mutations, oligometastatic disease
  • Five-step framework for evaluating remission possibilities — from biomarker review to MDT second opinion
  • Supportive care in China: TCM and integrative approaches to support treatment tolerance alongside standard oncology

Important Facts

  • Stage 4 remission is possible but requires a case-specific assessment — not a general population statistic
  • Biomarker and molecular testing is essential before evaluating remission potential
  • MDT review in China can clarify realistic treatment goals and whether local treatment to metastases is appropriate
  • Durable remission can be a meaningful and important goal even when the word "cure" is used carefully by oncologists
April 29, 2026
Treatment Guide

Blood Cancer Treatments Beyond Chemotherapy and CAR T

A calm, structured guide for international patients and caregivers on the full treatment landscape for blood cancers — covering targeted therapies, immunotherapy (monoclonal antibodies, bispecific antibodies), stem cell transplantation, combination strategies, and how MDT review in China supports structured treatment planning across leukemia, lymphoma, and myeloma.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • Targeted therapy, immunotherapy, and transplant options for leukemia, lymphoma, and myeloma beyond chemotherapy and CAR T
  • How treatment is sequenced across induction, consolidation, relapse, and bridge-to-transplant phases
  • Five-step framework for evaluating blood cancer treatment options in China
  • Supportive care in China: TCM and integrative approaches alongside oncology treatment

Important Facts

  • Blood cancer treatment is a dynamic sequence requiring molecular subtype confirmation and phase-appropriate evaluation
  • Bispecific antibodies are an increasingly important alternative to CAR T in relapsed/refractory settings
  • MDT review provides structured evaluation of all treatment options at each stage — applicable before any travel commitment
  • China offers advanced blood cancer treatments including targeted therapy, immunotherapy, transplant, and CAR T programmes at leading oncology centres
April 29, 2026
Cell Therapy Guide

CAR T-Cell Therapy for Solid Tumours: CT041 and the Claudin18.2 Breakthrough

A calm, structured guide for international patients and caregivers on the CT041 / Claudin18.2 CAR T breakthrough for advanced gastric cancer in China — covering why solid tumours have been difficult for CAR T, what the new data shows, why outcomes remain uncertain, how to assess eligibility, and how MDT review supports the decision-making process.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • CT041 (satri-cel) breakthrough: first randomised CAR T trial in solid tumours, improved survival in Claudin18.2-positive gastric cancer
  • Why outcomes remain uncertain: limited follow-up, selected patient populations, durability variation
  • Eligibility assessment: CLDN18.2 biomarker testing, prior treatment history, overall fitness
  • Six-step decision framework for international patients evaluating CAR T in China

Important Facts

  • CAR T for solid tumours is beginning to show results in specific CLDN18.2-positive cases — but is not yet broadly effective across all solid tumour types
  • CT041 represents a landmark milestone — the first randomised controlled evidence of CAR T improving survival in a solid tumour
  • Eligibility requires confirmed CLDN18.2 expression testing — this is not routinely included in standard cancer panels
  • For international patients in China, MDT review confirms eligibility and realistic expectations before any programme commitment is made
April 28, 2026
Long-Term Care Guide

What to Expect When Living with Treatable but Not Curable Cancer

A calm, structured guide for international patients and caregivers on the emotional and practical challenges of long-term cancer management — covering treatment decisions over time, a six-step decision framework, caregiver sustainability, and how TCM-based supportive care in China complements long-term oncology treatment.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • Why long-term cancer creates chronic uncertainty — and how patients and caregivers build resilience over time
  • How treatment decisions evolve across first-line, second-line, and third-line therapy
  • Six-step framework for navigating long-term cancer decisions in China
  • Supportive Care: TCM, acupuncture, and integrative approaches for long-term symptom management alongside oncology treatment

Important Facts

  • Long-term cancer management requires ongoing adaptation — not a single decision but a sustained process of planning and adjustment
  • Structured MDT review at key transition points provides clarity and direction when treatment options change or become uncertain
  • For international patients in China, continuity coordination — records, translation, follow-up — holds the long-term care experience together
  • TCM-based supportive care helps manage accumulated fatigue, sleep disruption, and emotional stress across the long-term cancer journey
April 28, 2026
Treatment Guide

How Do Targeted Cancer Drugs Find Cancer Cells?

A calm, structured guide for international patients and caregivers on how targeted cancer therapies work — covering molecular targeting mechanisms, why side effects still occur, how doctors use NGS and MDT review to select the right drug, a five-step decision framework for evaluating targeted therapy, and how supportive care in China can complement the treatment experience.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • How targeted drugs identify cancer cells through molecular markers such as HER2, EGFR, ALK, BRAF
  • Four mechanisms: blocking growth signals, triggering apoptosis, anti-angiogenesis, antibody-drug conjugates
  • How MDT review and molecular profiling determine whether targeted therapy is appropriate for a specific patient
  • Five-step decision framework for evaluating targeted therapy in China

Important Facts

  • Targeted therapy works only when specific molecular markers are confirmed — testing is the essential first step
  • Side effects can still occur because some molecular pathways are shared between cancer and normal cells
  • For international patients in China, MDT review confirms whether the recommended targeted drug is matched to the specific molecular profile
  • In China, TCM and supportive care can be integrated alongside targeted therapy to help manage side effects and improve daily tolerance
April 27, 2026
Supportive Care Guide

What to Expect When Managing Day-to-Day Health During Chemotherapy

A practical guide for international patients and caregivers on managing daily health during chemotherapy — nutrition, energy pacing, symptom monitoring, emotional balance, and how TCM-based supportive care in China can be safely integrated alongside standard oncology treatment to improve tolerance and quality of life.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • Four-domain practical framework: stabilise nutrition, manage energy proactively, monitor symptoms early, support emotional balance
  • Supportive care in China: clinical nutritional guidance, symptom management clinics, acupuncture, and TCM-based approaches integrated under supervision
  • Caregiver role: observation, routine maintenance, logistical coordination, and calm emotional presence during treatment
  • When to seek a second opinion or MDT review during chemotherapy — six practical scenarios

Important Facts

  • Managing chemotherapy day-to-day is about stability, not optimisation — small consistent habits matter more than occasional large efforts
  • In China, TCM and integrative approaches may support fatigue, nausea, appetite, and sleep alongside standard treatment — under clinical supervision
  • Caregivers are critical to treatment tolerance through observation, routine support, and communication with the care team
  • An MDT review can help confirm whether the current treatment plan — including supportive care — is optimally designed for the patient
April 27, 2026
Treatment Guide

Are There Cases of Cancer Patients Cured Without Chemotherapy?

A calm, structured guide for international patients and caregivers on when cancer can be successfully treated without chemotherapy — covering early-stage disease managed with surgery or radiation, how to evaluate recurrence risk and alternatives such as targeted or hormonal therapy, a six-step decision framework, caregiver guidance, and how MDT review in China supports correct treatment planning.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • Three-tier risk logic: low-risk localised disease (chemo often not needed) vs intermediate risk (case-by-case) vs high-risk systemic disease (often necessary)
  • Six-step decision framework: confirm stage, understand recurrence risk, weigh benefit vs burden, ask about alternatives, MDT review, structured plan
  • What patients misunderstand: comparing outcomes without accounting for different stage and tumour biology
  • Caregiver guidance: balancing fear of side effects with fear of under-treatment — and how to ask the right questions
  • Supportive care in China: TCM and acupuncture to manage fatigue, nausea, and recovery alongside chemotherapy

Important Facts

  • Chemotherapy is not always necessary — early-stage, localised disease may be fully managed with surgery or radiation alone
  • The right question is not "Can cancer be cured without chemo?" but "Does this specific cancer at this stage require it?"
  • Alternatives such as targeted or hormonal therapy may replace chemotherapy for some cancer types — but only if molecular testing confirms suitability
  • For international patients, MDT review helps clarify whether chemotherapy is essential, optional, or replaceable with another approach
April 26, 2026
Treatment Guide

How Does Prostate Cancer Stage Affect Treatment Decisions?

A calm, structured guide for international patients and caregivers on how prostate cancer stage — localised, locally advanced, or metastatic — determines whether surgery, radiation, hormone therapy, or chemotherapy is appropriate, with a six-step decision framework, risk classification, caregiver guidance, and MDT review coordination in China.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • The core concept: local disease requires local treatment; metastatic disease requires systemic treatment
  • A six-step decision framework: confirm staging → understand risk classification → clarify goal → compare options correctly → MDT review → coordinated execution
  • Risk stratification: what low, intermediate, and high risk mean for urgency and treatment approach
  • Caregiver role: asking stage-first questions, preventing rushed decisions, and supporting long-term management
  • Supportive care in China: how TCM and integrative approaches can help with hormone therapy side effects and overall wellbeing

Important Facts

  • Stage determines which treatments are appropriate — choosing treatment before confirming stage leads to suboptimal decisions
  • The right question is not "Which treatment is best?" but "Which treatment fits this stage and goal?"
  • For international patients, MDT review ensures staging and treatment logic are aligned before any commitment is made
  • Prostate cancer — especially metastatic disease — often requires long-term management, not a single intervention
April 24, 2026
Treatment Guide

Should You Have Surgery Immediately After Stomach Cancer Diagnosis?

A calm, structured guide for international patients and caregivers on stomach cancer surgery timing — when surgery is the first step, when neoadjuvant chemotherapy should come first, a six-step decision framework for treatment sequencing, caregiver guidance on avoiding panic-driven decisions, and how MDT review supports correct sequencing in China.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • Four direct answers on surgery timing: should it be immediate, what happens if surgery is too early, when is surgery the first step, and when to pause for a second opinion
  • Why stomach cancer treatment follows a sequence — not a single immediate action
  • A six-step decision framework: confirm staging → neoadjuvant therapy question → clarify goal → understand full sequence → MDT review → coordinated action
  • Caregiver role: preventing panic-driven decisions while supporting structured action
  • Supportive care in China: what TCM and integrative approaches can and cannot do alongside standard treatment

Important Facts

  • Surgery timing depends on stage and tumour characteristics — not simply how much time has passed since diagnosis
  • In locally advanced cases, neoadjuvant chemotherapy before surgery may lead to better outcomes than immediate surgery
  • The key question is not "Are we too late?" but "Do we have a clear treatment plan?"
  • A structured MDT review clarifies treatment sequencing before any irreversible commitment is made
April 20, 2026
Treatment Decision Guide

How to Make Cancer Treatment Decisions When Everything Feels Uncertain

A structured guide for international patients and caregivers on how to make cancer treatment decisions when uncertainty, multiple options, and emotional pressure make the next step hard to see — covering an eight-step decision framework, when to seek a second opinion or MDT review, the caregiver role, and how cancer treatment coordination works in China.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • Eight-step decision framework: confirm diagnosis → clarify treatment goal → list real options → compare criteria → identify source of uncertainty → MDT review → personal priorities → coordinated action
  • Why uncertainty arises: five distinct sources — new diagnosis, complex treatment language, differing doctors, unspoken priorities, and cross-border complexity
  • When to pause and seek a second opinion or MDT consultation before starting treatment
  • Caregiver decision-support role: five practical strategies for reducing pressure without taking over
  • How supportive care in China (including TCM) integrates alongside standard oncology treatment — not as an alternative

Important Facts

  • Uncertainty in cancer care usually has a specific source — naming it is the first step to addressing it
  • Many patients are not confused about the treatment; they are confused about what the treatment is trying to accomplish
  • A second opinion or MDT review is often more useful than more general searching when decision confidence is low
  • Personal priorities — quality of life, location, intensity, cost — are not secondary; they are part of how real decisions are made
April 18, 2026
CAR-T Cost Guide

How Much Does CAR-T Cost in China for International Patients?

A clear cost breakdown for international patients and caregivers — covering what CAR-T actually costs in China (CNY 1,100,000–1,650,000 total), what that price includes across eight cost components, how it compares to US pricing, and how to make a financially informed treatment decision with an MDT review before committing.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • Full 8-component cost breakdown: drug, bridging therapy, chemotherapy, hospitalization, testing, side-effect management, supportive care, and follow-up
  • Global comparison: China (USD 150,000–230,000) vs US (USD 370,000–550,000+ drug cost alone)
  • Why total cost varies: side-effect severity, ICU usage, and bridging therapy are the main drivers of cost uncertainty
  • A 6-step framework: confirm eligibility → clarify goal → compare alternatives → evaluate timing → MDT review → plan logistics
  • Data updated April 2026 — sources include NMPA, National Healthcare Security Administration, and public market information

Important Facts

  • CAR-T cost is a multi-stage treatment journey — the drug accounts for 70–80% but the surrounding process adds meaningful cost
  • Side-effect management (CRS, ICANS) is the most variable cost component — severity and ICU use drive the upper range
  • Lower cost in China does not mean simpler decision — correct indication, sequencing, and experienced centre all still matter
  • International patients should request a full treatment cost estimate, not just the drug price, before any financial planning
April 17, 2026
Treatment Decision Guide

How to Choose the Right Cancer Treatment Plan After Diagnosis

A structured decision guide for international patients and caregivers on how to choose the right cancer treatment plan — covering how to confirm staging, compare treatment options, understand treatment goals, use MDT review, sequence treatment steps, and access coordinated cancer treatment planning in China.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • Why treatment choice is a sequence, not a single decision — and why sequencing logic matters more than any individual therapy
  • An eight-step decision framework: from confirming diagnosis to moving into coordinated execution
  • Four core answer blocks: what to do after diagnosis, how to compare options, when to seek a second opinion, and how MDT helps
  • How caregivers support better treatment decisions — emotionally, practically, and structurally
  • How supportive care including TCM integrates alongside standard oncology treatment in China

Important Facts

  • The most important decision is not just what treatment — but what comes first, what comes next, and why
  • Treatment goal clarity is the foundation: cure, recurrence reduction, disease control, or symptom relief all lead to different option comparisons
  • A structured MDT review turns multiple specialist opinions into one coherent plan before any irreversible decisions are made
  • For international patients in China, the coordination process is part of the treatment decision itself — not a separate logistical afterthought
April 17, 2026
Treatment Decision Guide

How to Decide Between CAR-T and Other Cancer Therapy After Relapse

A structured decision guide for international patients and caregivers navigating the choice between CAR-T cell therapy and other cancer treatments — covering when CAR-T is appropriate, what alternatives to compare, a six-step decision framework, caregiver role, and how MDT review can reduce uncertainty before committing to treatment in China.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • Why CAR-T is not a universal alternative — and how disease type and setting determine eligibility
  • Five questions to ask before deciding between CAR-T and other therapy: from diagnosis clarity to treatment goal
  • A six-step decision framework: from disease confirmation to MDT review to coordinated execution
  • How caregivers can support good decisions without adding emotional pressure
  • How supportive care including TCM integrates alongside — not instead of — CAR-T treatment in China

Important Facts

  • CAR-T is a distinct treatment pathway — not simply a stronger version of chemotherapy or other systemic therapy
  • The right question is not "Is CAR-T the most advanced?" but "Is CAR-T appropriate for this case at this point?"
  • A structured MDT review is most useful before committing to CAR-T — not after several other options have already failed
  • For international patients in China, practical coordination is inseparable from medical eligibility — both must be assessed together
April 11, 2026
Gene Therapy Guide

Gene Editing for Beta-Thalassemia: What International Patients Should Know About CS-101 and Treatment in China

A plain-language guide to CS-101 base editing gene therapy for beta-thalassemia — covering the Nature-published clinical trial results, how base editing differs from CRISPR, eligibility for international and adult patients, the treatment process, and how to arrange a specialist consultation in China.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • CS-101 base editing achieved transfusion-free status in all 5 trial patients — results published in Nature
  • How base editing differs from CRISPR: a more precise, single-letter DNA change without strand cutting
  • Access for adult patients: CS-101 is not subject to the under-16 age restriction of bone marrow transplant
  • What international patients should prepare: genetic mutation records, transfusion history, iron overload status
  • Current status: CS-101 is in active IND clinical trials and not yet commercially approved

Important Facts

  • The CS-101 trial is the first Chinese gene-editing drug result published in Nature — a significant international milestone
  • Transfusion-free outcomes were achieved within an average of 16 days, maintained over 23 months of follow-up
  • International patients interested in access should begin with a structured specialist consultation to understand eligibility and timing
  • A well-coordinated second opinion or MDT review is the recommended starting point before any treatment decision
April 7, 2026
Blood Cancer Treatment

Beijing Protocol: Haploidentical Stem Cell Transplant — Evidence for International Patients

A plain-language guide to the clinical evidence behind China's most widely used approach to half-matched donor transplantation — covering published outcomes data, patient eligibility, disease indications including leukaemia and aplastic anaemia, caregiver considerations, and post-transplant follow-up for international patients.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • What the Beijing Protocol is and how it differs from traditional matched-donor transplantation
  • Clinical evidence from peer-reviewed journals including Haematologica, Blood, and Journal of Clinical Oncology
  • Key outcomes data: survival rates comparable to fully matched sibling transplants
  • Modified protocols for older patients (aged 55–65) — Phase II trial evidence
  • Integration of CAR-T therapy with haploidentical HSCT for relapsed or refractory B-cell ALL

Important Facts

  • The Beijing Protocol is documented in international peer-reviewed journals — not centre-specific claims
  • Nearly every patient has a haploidentical family donor available — half-matched is sufficient
  • Eligibility for older patients has expanded significantly through modified conditioning regimens
  • A structured MDT review of existing records is the recommended first step for international patients
April 7, 2026
Lymphoma Guide

Follicular Lymphoma Treatment Options: What Should You Do Next?

A clear guide for international patients and caregivers on follicular lymphoma treatment — covering watchful waiting, immunotherapy, targeted therapy, chemotherapy, and CAR-T therapy for relapsed disease, with guidance on when to treat and how MDT evaluation supports timing decisions.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • Why watchful waiting is a legitimate first approach for some follicular lymphoma patients
  • Immunotherapy: when it is used alone and when combined with chemotherapy
  • Targeted therapy options for progression or relapse
  • CAR-T therapy for relapsed or refractory follicular lymphoma — eligibility and process
  • How to think about treatment timing — the most important and often hardest question

Important Facts

  • The key question for follicular lymphoma is often "when to treat" — not just "what to treat with"
  • Watchful waiting is an active, monitored strategy — not inaction
  • A second opinion can help confirm that monitoring or treatment timing is appropriate
  • A structured MDT review is the most effective starting point for international patients
April 7, 2026
Lymphoma Guide

Diffuse Large B-Cell Lymphoma Treatment Options: What Should You Do Next?

A clear guide for international patients and caregivers on DLBCL treatment approaches — covering first-line chemoimmunotherapy, radiation, targeted therapy, stem cell transplant, and CAR-T therapy for relapsed or refractory disease, with guidance on second opinion and MDT evaluation.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • Standard first-line treatment: chemotherapy combined with immunotherapy
  • When radiation therapy is used in DLBCL — and when it is not
  • Targeted therapy options for specific molecular subtypes
  • Stem cell transplant: when it is considered and what eligibility involves
  • CAR-T therapy for relapsed or refractory DLBCL — eligibility and process

Important Facts

  • Not all DLBCL cases are the same — molecular subtype and stage drive treatment decisions
  • A second opinion can help confirm diagnosis and evaluate whether the proposed treatment is optimal
  • CAR-T therapy is typically used after prior treatment lines — not as first-line therapy
  • A structured MDT review is the most effective starting point for international patients
April 6, 2026
CAR-T Guide

Side Effects of CAR-T Therapy: What Patients Should Know

A calm, clear guide for international patients and caregivers on what CAR-T therapy side effects to expect — covering cytokine release syndrome (CRS), neurological symptoms (ICANS), blood count changes, infection risk, fatigue, and what hospital monitoring looks like in China.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • Cytokine release syndrome (CRS): what it is, when it happens, and how it is managed
  • Neurological symptoms (ICANS): what patients may experience and why
  • Blood count changes, infection risk, and fatigue during recovery
  • Why understanding side effects helps — not hinders — treatment decisions
  • What hospital monitoring looks like for international patients in China

Important Facts

  • CAR-T side effects are immune-related, not drug toxicity — they work differently from chemo
  • Most side effects occur in the first days to weeks after infusion under hospital monitoring
  • Side effects should be understood alongside disease stage and treatment goals — not in isolation
  • A structured MDT review is the right first step before making CAR-T decisions
April 6, 2026
Treatment Guide

CAR-T vs Targeted Therapy: What's the Difference and How Do You Decide?

A clear guide for international patients comparing CAR-T therapy and targeted therapy — covering how each works, the key difference between molecular precision and immune cell engineering, when each is typically used, and how a multidisciplinary review helps determine the most appropriate treatment sequence.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • How targeted therapy and CAR-T therapy differ — molecular blocking vs immune cell reprogramming
  • Why targeted therapy is often used earlier and CAR-T typically comes after prior treatment lines
  • What makes the comparison complex and how an MDT review brings clinical clarity
  • Step-by-step preparation guide for international patients evaluating advanced treatment options
  • What to expect from structured evaluation and multidisciplinary decision support in China

Important Facts

  • Targeted therapy blocks cancer pathways; CAR-T engineers immune cells — fundamentally different strategies
  • The question is not which is "better" but which is appropriate at this stage of the disease
  • Molecular profile and treatment history determine which option is even available
  • A structured MDT review is the appropriate starting point before any advanced treatment decision
April 6, 2026
Treatment Guide

CAR-T vs Chemotherapy: What's the Difference and How Do You Decide?

A clear guide for international patients comparing CAR-T therapy and chemotherapy — covering how each works, when each is typically used, side effect profiles, and how a multidisciplinary review helps determine the most appropriate treatment at each stage of the cancer journey.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • How CAR-T therapy and chemotherapy differ — mechanism, timing, and side effect profiles
  • Why CAR-T is typically used after relapse, not as first-line treatment
  • What factors make treatment decisions complex and how an MDT review brings clarity
  • Step-by-step preparation guide for international patients comparing treatment options
  • What to expect from structured evaluation and MDT-based decision support in China

Important Facts

  • CAR-T and chemotherapy are not interchangeable — they serve different roles at different stages
  • The question is not which is "better" but which is appropriate for this patient at this stage
  • Treatment decisions are clinical determinations, not patient choices made in isolation
  • A structured MDT review is the appropriate first step before any major treatment decision
April 5, 2026
Treatment Guide

Lymphoma Treatment After Relapse: What Options Exist and How to Decide

A clear guide for international patients and caregivers facing lymphoma relapse — covering the main treatment options (salvage chemotherapy, targeted therapy, stem cell transplant, CAR-T), why a second opinion is especially valuable at this stage, and how to access structured evaluation and MDT review in China.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • Five treatment approaches at relapse: salvage chemotherapy, targeted therapy, immunotherapy, stem cell transplant, and CAR-T
  • Why relapse is one of the most important moments to seek a structured second opinion or MDT review
  • What factors doctors reassess at relapse and why treatment becomes highly personalized
  • How international patients prepare medically and logistically for relapse evaluation in China
  • What to expect in terms of monitoring, strategy adjustment, and advanced therapy timing after relapse

Important Facts

  • Lymphoma relapse does not mean treatment options have run out — it is a recognized stage requiring strategy reassessment
  • Treatment at relapse is highly individualized: what was used before, how long it worked, and current disease status all matter
  • A second opinion or MDT review at relapse often provides the clearest picture of available options and sequencing
  • You are not starting over — you are continuing a treatment journey, with new decisions ahead
April 5, 2026
Treatment Guide

Lymphoma Treatment Options Explained: A Clear Guide for Patients and Families

A clear guide to the main treatment approaches for lymphoma — covering chemotherapy, immunotherapy, targeted therapy, radiation, stem cell transplant, and CAR-T therapy — and how international patients can access structured evaluation and treatment coordination in China.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • Six main treatment approaches: chemotherapy, immunotherapy, targeted therapy, radiation, stem cell transplant, and CAR-T
  • Why lymphoma subtype — DLBCL, Hodgkin, follicular, mantle cell — determines the treatment approach
  • When CAR-T therapy is typically considered and what eligibility involves for international patients
  • How international patients prepare medically and logistically for lymphoma evaluation in China
  • The role of caregivers and why shared decision-making matters in lymphoma care

Important Facts

  • Lymphoma is not a single disease — subtype confirms the treatment direction before any plan is formed
  • Treatment decisions are often complex and personalized: a structured second opinion or MDT review can provide important clarity
  • CAR-T therapy is typically considered after relapse, and eligibility requires thorough multidisciplinary evaluation
  • Understanding your options does not remove uncertainty — but it helps you move forward with greater confidence
April 5, 2026
Treatment Guide

Multiple Myeloma Treatment After Relapse: What Options Exist and How to Decide

A clear guide for international patients and caregivers facing myeloma relapse — covering the main treatment options (new drug combinations, targeted therapies, CAR-T), why a second opinion matters most at this stage, and how to access structured evaluation and MDT review in China.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • Four treatment approaches at relapse: changing drug combinations, novel therapies, CAR-T therapy, and clinical strategy adjustments
  • Why relapse is one of the most important moments to seek a structured second opinion or MDT review
  • What factors doctors assess at relapse and why treatment becomes highly personalized
  • How international patients prepare medically and logistically for relapse evaluation in China
  • What to expect in terms of monitoring, strategy adjustment, and advanced therapy timing after relapse treatment

Important Facts

  • Myeloma relapse does not mean treatment options have run out — it is a recognized part of long-term disease management
  • Treatment at relapse is highly personalized: what was used before, how long it worked, and current disease status all matter
  • A second opinion or MDT review at relapse often provides the clearest picture of available options and timing
  • You are not starting from zero — you are continuing a treatment journey, with new decisions ahead
April 5, 2026
Treatment Guide

Multiple Myeloma Treatment Options Explained: A Clear Guide for Patients and Families

A clear guide to the main treatment pathways for multiple myeloma — covering targeted therapy combinations, stem cell transplant, maintenance, relapsed disease, and CAR-T therapy — and how international patients can access structured evaluation and treatment coordination in China.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • Five main treatment approaches: targeted therapy combinations, stem cell transplant, maintenance therapy, relapsed disease options, and CAR-T
  • What determines treatment selection — stage, risk classification, prior treatments, and patient health
  • When CAR-T therapy is typically considered and what eligibility involves
  • How international patients prepare medically and logistically for myeloma evaluation in China
  • The role of caregivers in long-term myeloma care and decision-making

Important Facts

  • Multiple myeloma is often managed as a long-term condition — treatment evolves across phases rather than following a single fixed path
  • Treatment selection depends on disease stage, risk classification, transplant eligibility, and prior treatment history
  • CAR-T therapy is typically considered after relapse, and eligibility requires thorough MDT-based evaluation
  • Understanding your options does not make the journey simple — but it makes it more navigable
April 4, 2026
Decision Guide

CAR-T Therapy for Multiple Myeloma: Who Is Eligible and What to Expect

A guide for international patients on CAR-T therapy eligibility for multiple myeloma — covering disease status, prior treatment requirements, the step-by-step process, preparation, and what to expect when coordinating care in China.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • Five eligibility factors: disease status, prior therapies, overall health, disease burden, and MDT-based review
  • Six-step treatment process from evaluation through leukapheresis, cell engineering, conditioning, infusion, and monitoring
  • Why eligibility assessment for myeloma CAR-T requires pathology, imaging, and multidisciplinary discussion
  • What international patients should prepare medically and logistically before and during treatment
  • The role of caregivers and why their own wellbeing also needs planning

Important Facts

  • CAR-T for myeloma is typically considered after relapse or when prior therapies are no longer working
  • Eligibility requires a thorough clinical evaluation — not a simple checklist
  • International patients often begin with a remote MDT consultation before traveling to confirm appropriateness
  • Clarity before commitment: understanding the process reduces both uncertainty and avoidable urgency
April 4, 2026
Decision Guide

CAR-T Therapy for Lymphoma: Who Is Eligible and What to Expect

A detailed guide for international patients on CAR-T therapy eligibility for lymphoma — covering eligibility criteria, the step-by-step treatment process, how to prepare medically and logistically, what to expect in China, and why starting with a structured MDT review matters.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • Five eligibility factors doctors assess: lymphoma subtype, disease status, prior treatments, overall health, and disease burden
  • Six-step process from evaluation through leukapheresis, cell engineering, conditioning, infusion, and monitoring
  • Why eligibility for CAR-T requires pathology confirmation, PET-CT review, and multidisciplinary discussion
  • What international patients should prepare medically and logistically before and during treatment
  • The role of caregivers throughout CAR-T treatment — and why their wellbeing also needs planning

Important Facts

  • CAR-T is not a first-line treatment — it is typically considered after relapse or when prior therapies have been insufficient
  • Eligibility is not a simple checklist: it requires pathology, imaging, and MDT review before any treatment is confirmed
  • International patients often begin with a remote MDT consultation before traveling to confirm appropriateness
  • Clarity before commitment: taking time to understand the full process reduces both uncertainty and avoidable urgency
April 2, 2026
Treatment Guide

CAR-T Therapy in China: What Foreign Patients Should Know

A guide to CAR-T cell therapy for lymphoma in China — how it works, who may be eligible, what the treatment process involves for international patients, and why a structured second opinion matters before deciding.

ChinaMed Waypoint
Read Full Article

Key Highlights

  • Step-by-step explanation of the CAR-T therapy process from cell collection to monitoring
  • Which types of lymphoma are most commonly considered for CAR-T
  • Why eligibility is strict and CAR-T is not a first-line treatment
  • Key risks including cytokine release syndrome (CRS) and how hospitals manage them
  • How to prepare medically and logistically for a CAR-T treatment visit to China

Important Facts

  • CAR-T therapy in China is available to eligible foreign patients, but requires thorough clinical evaluation before any treatment is arranged
  • Most patients begin with a remote second opinion or MDT review before traveling to determine suitability
  • Post-infusion monitoring requires staying near the treating hospital — travel planning must account for this
  • A well-informed, unhurried approach to decision-making is more important than speed

Need Personalised Cancer Care Guidance?

Our medical coordinators can help you understand your options, connect with oncology specialists, and navigate cancer care in China.

Get ConsultationAll Resources